PMID- 23225431
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20121210
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 32
IP  - 12
DP  - 2012 Dec
TI  - Detection of numerical abnormalities of chromosome 9 and p16/CDKN2A gene 
      alterations in ovarian cancer with fish analysis.
PG  - 5309-13
AB  - BACKGROUND: The molecular events leading to the development of ovarian cancer are 
      not well-established. Defects of the retinoblastoma protein (pRb)/cyclin-D1/p16 
      pathway have been shown to play a critical role in the development of human 
      malignancies. In particular, the p16/cyclin-dependent kinase inhibitor 2A 
      (CDKN2A) gene located on chromosomal region 9p21 frequently is altered in several 
      types of cancer. MATERIALS AND METHODS: To investigate both the presence of 
      numerical abnormalities of chromosome 9 and p16 gene alterations in ovarian 
      cancer, we studied 28 cases by the fluorescence in situ hybridization (FISH) 
      technique using a DNA p16 probe and an a-satellite probe specific for chromosome 
      9. RESULTS: Numerical abnormalities of chromosome 9 were found in all studied 
      cases. Polysomy 9 was detected in 10 cases while monosomy 9 in seven cases. In 11 
      cases, there were two cell populations, one with polysomy 9 and the other with 
      monosomy 9. In all cases, the p16 gene deletion was observed. Among them, 25 
      cases presented deletion of p16 gene in 21.43%-86.3% of the examined cells. Three 
      cases carried deletion of the p16 gene in a lower proportion (12.04%-19.49%). In 
      five cases with p16 gene deletion, homozygous deletion was detected. CONCLUSION: 
      Numerical aberrations of chromosome 9 and p16 gene deletion are common findings 
      in ovarian cancer. Data suggest that the p16 gene, located in the short arms of 
      chromosome 9, may play a role in ovarian carcinogenesis. In addition, polysomy 9 
      could lead to activation of a number of oncogenes, thus participating in the 
      neoplastic process in the ovaries.
FAU - Aravidis, Christos
AU  - Aravidis C
AD  - Department of Cancer Genetics, Centrum for Molecular Medicine, Karolinska 
      University Hospital, L8:02 Stockholm171 76, Sweden. christos.aravidis@yahoo.gr
FAU - Panani, Anna D
AU  - Panani AD
FAU - Kosmaidou, Zoi
AU  - Kosmaidou Z
FAU - Thomakos, Nikolaos
AU  - Thomakos N
FAU - Rodolakis, Alexandros
AU  - Rodolakis A
FAU - Antsaklis, Aristeidis
AU  - Antsaklis A
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Transformation, Neoplastic/genetics
MH  - *Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 9
MH  - Female
MH  - *Gene Deletion
MH  - *Genes, p16
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Ovarian Neoplasms/*genetics
EDAT- 2012/12/12 06:00
MHDA- 2013/05/03 06:00
CRDT- 2012/12/11 06:00
PHST- 2012/12/11 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
AID - 32/12/5309 [pii]
PST - ppublish
SO  - Anticancer Res. 2012 Dec;32(12):5309-13.